Samuel Reid, MD
Internal Medicine · Spartanburg, SCNPI 1861463945
Payments from drug & device makers
Across 185 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$553
- Novartis$341
- Astellas Pharma US Inc$300
- Amarin Pharma, Inc.$214
- Novo Nordisk$119
- Sanofi-aventis U.S. LLC$117
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,86599%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 43 | $553 |
| Novartis | 20 | $341 |
| Astellas Pharma US Inc | 17 | $300 |
| Amarin Pharma, Inc. | 15 | $214 |
| Novo Nordisk | 8 | $119 |
| Sanofi-aventis U.S. LLC | 7 | $117 |
| Medtronic | 4 | $110 |
| AbbVie | 7 | $102 |
| GSK | 5 | $80 |
| Phathom Pharmaceuticals, Inc. | 4 | $72 |
| Gilead | 3 | $69 |
| Radius Health, Inc. | 3 | $68 |
| AstraZeneca | 5 | $65 |
| Pfizer | 5 | $64 |
| Dexcom, Inc. | 3 | $55 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| Abbott | 2 | $37 |
| Eisai Inc. | 3 | $36 |
| Inari Medical, Inc. | 1 | $33 |
| Dynavax Technologies Corporation | 2 | $32 |
| Lilly USA, LLC | 2 | $29 |
| Exact Sciences | 2 | $29 |
| Johnson & Johnson | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Merck | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Boehringer Ingelheim | 2 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
How this compares
$2,891 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $136,447 |
| JanuviaSitagliptin Phosphate | 52 | $55,297 |
| FarxigaDapagliflozin Propanediol | 67 | $52,241 |
| RybelsusSemaglutide | 24 | $35,539 |
| JardianceEmpagliflozin | 34 | $28,030 |
| Repatha SureclickEvolocumab | 36 | $24,104 |
| OzempicSemaglutide | 24 | $21,795 |
| MyrbetriqMirabegron | 41 | $18,220 |
| XareltoRivaroxaban | 15 | $17,456 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $16,315 |
| InvokanaCanagliflozin | 12 | $15,684 |
| Rosuvastatin Calcium | 574 | $14,601 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $7,993 |
| Ezetimibe | 142 | $7,092 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $6,304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $136,447142 claims |
| Novo NordiskRybelsus, Ozempic | $119 | $57,33348 claims |
| MerckJanuvia | $27 | $55,29752 claims |
| AstraZenecaFarxiga | $65 | $52,24167 claims |
| Johnson & JohnsonXarelto, Invokana | $28 | $33,14027 claims |
| Boehringer IngelheimJardiance | $23 | $28,03034 claims |
| Astellas Pharma US IncMyrbetriq | $300 | $18,22041 claims |
| GSKTrelegy Ellipta | $80 | $7,99313 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $11 | $5,57212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Spartanburg
- Suzanne KovacsSpartanburg$14K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.